PerkinElmer, Cepheid, Biotage | GenomeWeb

PerkinElmer, Cepheid, Biotage


This week, PerkinElmer launched its BioXpression biomarker platform, which "can speed the discovery of biomarkers" through its biomarker sample-enrichment technology and "highly accurate" mass pattern recognition approach, the company said this week in a statement. The BioXpression platform uses the company's proteomic signature technology that "delivers high throughput and ultra-high mass accuracy and stability, resulting in comprehensive and high-confidence" proteomic signatures, the company said

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.